Related Experiment Video

Updated: Aug 13, 2025

Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells
10:33

Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells

Published on: November 18, 2022

1.4K

Advances in Anti-Diabetic Cognitive Dysfunction Effect of Erigeron Breviscapus (Vaniot) Hand-Mazz

Shanye Gu1, Ziyi Zhou1,2,3, Shijie Zhang1,2,3

  • 1The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.

Pharmaceuticals (Basel, Switzerland)
|January 21, 2023
PubMed

Insights

Diabetic cognitive dysfunction (DCD) impairs memory and cognition. Erigeron breviscapus (EBHM), a Chinese herb, shows promise in treating DCD by targeting multiple pathways, offering a novel therapeutic avenue.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Diabetology

Background:

  • Diabetic cognitive dysfunction (DCD) is a progressive decline in cognitive functions linked to diabetes.
  • Current treatments for DCD are suboptimal, necessitating novel therapeutic strategies.
  • Potential DCD mechanisms include insulin resistance, amyloid-beta, tau hyperphosphorylation, oxidative stress, and neuroinflammation.

Purpose of the Study:

  • To review the pathophysiology of DCD.
  • To evaluate the therapeutic potential of Erigeron breviscapus (EBHM) for DCD.
  • To summarize EBHM's pharmacological mechanisms and active components relevant to DCD treatment.

Main Methods:

  • Literature review of DCD pathophysiology and EBHM's effects.
  • Analysis of studies on EBHM and its active components in cognitive disorders.
  • Synthesis of information on EBHM's anti-DCD properties.

Main Results:

  • EBHM possesses diverse pharmacological effects applicable to cognitive disorders.
  • EBHM's multi-component, multi-pathway, and multi-target synergistic activities are beneficial for DCD.
  • Specific active components and mechanisms of EBHM for DCD treatment were identified.

Conclusions:

  • EBHM presents a promising therapeutic agent for preventing and treating DCD.
  • Further research into EBHM's efficacy and mechanisms in DCD is warranted.
  • Chinese herbal medicine, like EBHM, offers a valuable approach to managing DCD.
Keywords:
Erigeron breviscapus (vant.) hand-mazz.active ingredientsdiabetic cognitive dysfunctionpathogenesispharmacological effects

More Related Videos

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

1.6K
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

625

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
180
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
233
Psychoneuroimmunology: Diabetes and Cancer01:19

Psychoneuroimmunology: Diabetes and Cancer

Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
55
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
327
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
226
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
481